Amy J Ramsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3696771/publications.pdf Version: 2024-02-01



AMVIRAMSEV

#	Article	lF	CITATIONS
1	A role for endothelial NMDA receptors in the pathophysiology of schizophrenia. Schizophrenia Research, 2022, 249, 63-73.	2.0	9
2	Schizophrenia: a disorder of broken brain bioenergetics. Molecular Psychiatry, 2022, 27, 2393-2404.	7.9	26
3	Abnormal sensory perception masks behavioral performance of Grin1 knockdown mice. Genes, Brain and Behavior, 2022, 21, .	2.2	2
4	Consequences of NMDA receptor deficiency can be rescued in the adult brain. Molecular Psychiatry, 2021, 26, 2929-2942.	7.9	34
5	A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology, 2021, 46, 413-422.	5.4	9
6	Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. Journal of Neurochemistry, 2021, 158, 960-979.	3.9	22
7	Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. Neuropharmacology, 2021, 199, 108805.	4.1	25
8	Chronic social isolation exerts opposing sex-specific consequences on serotonin neuronal excitability and behaviour. Neuropharmacology, 2020, 168, 108015.	4.1	23
9	Progressive neuroanatomical changes caused by Grin1 loss-of-function mutation. Neurobiology of Disease, 2019, 132, 104527.	4.4	24
10	Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophrenia. Scientific Reports, 2019, 9, 5087.	3.3	44
11	Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments. Molecular Neurobiology, 2019, 56, 4492-4517.	4.0	34
12	Neuron-specific deficits of bioenergetic processes in the dorsolateral prefrontal cortex in schizophrenia. Molecular Psychiatry, 2019, 24, 1319-1328.	7.9	41
13	Defects in Bioenergetic Coupling in Schizophrenia. Biological Psychiatry, 2018, 83, 739-750.	1.3	67
14	Restoring striatal WAVE-1 improves maze exploration performance of GluN1 knockdown mice. PLoS ONE, 2018, 13, e0199341.	2.5	1
15	Behavioral Effects of a Potential Novel TAAR1 Antagonist. Frontiers in Pharmacology, 2018, 9, 953.	3.5	8
16	Dexmedetomidine Prevents Excessive γ-Aminobutyric Acid Type A Receptor Function after Anesthesia. Anesthesiology, 2018, 129, 477-489.	2.5	44
17	Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia. Schizophrenia Bulletin, 2017, 43, sbw173.	4.3	26
18	Vulnerability to omega-3 deprivation in a mouse model of NMDA receptor hypofunction. NPJ Schizophrenia, 2017, 3, 12.	3.6	14

Amy J Ramsey

#	Article	IF	CITATIONS
19	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nature Communications, 2017, 8, 1791.	12.8	103
20	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M ₁ PAM VU6004256. ACS Chemical Neuroscience, 2016, 7, 1706-1716.	3.5	39
21	<i>α</i> 5GABA _A receptor deficiency causes autismâ€like behaviors. Annals of Clinical and Translational Neurology, 2016, 3, 392-398.	3.7	43
22	Changes in dendritic spine density in the nucleus accumbens do not underlie ethanol sensitization. Synapse, 2015, 69, 607-610.	1.2	5
23	Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiology of Disease, 2015, 74, 66-75.	4.4	119
24	Differential effects of NMDA receptor antagonism on spine density. Synapse, 2015, 69, 52-56.	1.2	20
25	Diazepam improves aspects of social behaviour and neuron activation in <scp>NMDA</scp> receptorâ€deficient mice. Genes, Brain and Behavior, 2014, 13, 592-602.	2.2	19
26	Sustained <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor hypofunction remodels the dopamine system and impairs phasic signaling. European Journal of Neuroscience, 2014, 40, 2255-2263.	2.6	15
27	<scp>NMDA</scp> receptorâ€deficient mice display sexual dimorphism in the onset and severity of behavioural abnormalities. Genes, Brain and Behavior, 2014, 13, 850-862.	2.2	41
28	N-terminal tagging of the dopamine transporter impairs protein expression and trafficking in vivo. Molecular and Cellular Neurosciences, 2014, 61, 123-132.	2.2	11
29	Preparation of Synaptic Plasma Membrane and Postsynaptic Density Proteins Using a Discontinuous Sucrose Gradient. Journal of Visualized Experiments, 2014, , e51896.	0.3	38
30	Chronic SSRI Treatment Exacerbates Serotonin Deficiency in Humanized <i>Tph2</i> Mutant Mice. ACS Chemical Neuroscience, 2013, 4, 84-88.	3.5	39
31	D ₁ Dopamine Receptor Coupling to PLCÎ ² Regulates Forward Locomotion in Mice. Journal of Neuroscience, 2013, 33, 18125-18133.	3.6	46
32	Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-D-aspartate currents by dopamine D1 receptor activation in striatum. Frontiers in Systems Neuroscience, 2011, 5, 28.	2.5	46
33	Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5795-5800.	7.1	71
34	NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Progress in Brain Research, 2009, 179, 51-58.	1.4	38
35	Hyperdopaminergia and NMDA Receptor Hypofunction Disrupt Neural Phase Signaling. Journal of Neuroscience, 2009, 29, 8215-8224.	3.6	86
36	MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3507-3512.	7.1	265

Amy J Ramsey

#	Article	IF	CITATIONS
37	Altered Markers of Tonic Inhibition in the Dorsolateral Prefrontal Cortex of Subjects With Schizophrenia. American Journal of Psychiatry, 2009, 166, 450-459.	7.2	77
38	Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cellular Signalling, 2009, 21, 87-94.	3.6	36
39	Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4405-4410.	7.1	170
40	Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor. Molecular Pharmacology, 2008, 74, 585-594.	2.3	135
41	Genetic NMDA Receptor Deficiency Disrupts Acute and Chronic Effects of Cocaine but not Amphetamine. Neuropsychopharmacology, 2008, 33, 2701-2714.	5.4	42
42	Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social Recognition. Neuron, 2006, 51, 601-612.	8.1	208